Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer

Creative Commons License

Mishra R. R., Belder N., Ansari S. A., Kayhan M., Bal H., Raza U., ...Daha Fazla

CLINICAL CANCER RESEARCH, cilt.24, sa.8, ss.1987-2001, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 24 Sayı: 8
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1158/1078-0432.ccr-17-2776
  • Dergi Adı: CLINICAL CANCER RESEARCH
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1987-2001
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Purpose: Tamoxifen remains an important hormonal therapy for ER-positive breast cancer; however, development of resistance is a major obstacle in clinics. Here, we aimed to identify novel mechanisms of tamoxifen resistance and provide actionable drug targets overcoming resistance.